Results 31 to 40 of about 26,349 (219)
Advanced Healthcare Materials, EarlyView.This review examines how cellular behavior is regulated by mechanical cues transmitted through soft biomaterials, from single‐cell mechanosensing to tissue‐level adaptation. It highlights why physiological relevance, rather than model complexity alone, is critical for translational mechanobiology and introduces a scoring framework linking material ...
Mathias Polz +9 more
wiley +1 more source
Cardiac Myosin Inhibition for Treatment of LVOT Obstruction in a Patient With Severe AS
JACC: Case ReportsAortic stenosis and obstructive hypertrophic cardiomyopathy are common conditions. When both are present in the same patient, the management can be challenging.
Ronald H. Wharton, MD +4 more
doaj +1 more source
Cardiomyocyte Specific Deletion of ADAR1 Causes Severe Cardiac Dysfunction and Increased Lethality
Frontiers in Cardiovascular Medicine, 2020 Background: Adenosine deaminase acting on RNA 1 (ADAR1) is a double-stranded RNA-editing enzyme that is involved in several functions including the deamination of adenosine to inosine, RNA interference (RNAi) mechanisms and microRNA (miRNA) processing ...
Hamid el Azzouzi +11 more
doaj +1 more source
Progress in New Therapies Targeting the Pathogenesis of Cardiomyopathywith Hypertrophic Phenotype
罕见病研究, 2023 Hypertrophic cardiomyopathy (HCM) is cardiomyopathy with a clinical phenotype of cardiac hypertrophy. The etiology includes genetically defective encoding sarcomeres, congenital metabolic diseases such as lysosomal storage diseases, systemic amyloidosis ...
LIU Yanbo, TIAN Zhuang, ZHANG Shuyang
doaj +1 more source
Bioprinting High‐Cell‐Density Cardiac Tissue Constructs With Sustained Contractile Function
Advanced Healthcare Materials, EarlyView.Contractile cardiomyocytes in 3D culture provide insights into the behavior of the heart. Combining a 3D bioprinting approach with a multi‐electrode array allows the development of the 3D culture to be monitored over time, and matured cultures allow the effect of drugs on cardiac function to be modelled, replicating effects seen in clinical application.
Priscila Melo +8 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in ...
Caroline J. Coats +35 more
doaj +1 more source
Advanced Healthcare Materials, EarlyView.A heart‐on‐a‐chip model of dilated cardiomyopathy is developed from patient‐derived induced pluripotent stem cells. The model recapitulates key disease phenotypes and enables functional assessment through integrated bead‐based tracking and pillar deflection measurements.
Ali Mousavi +10 more
wiley +1 more source
Frontiers in Cardiovascular MedicineMavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM).
Daniel Seung Kim +92 more
doaj +1 more source
Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?
ESC Heart Failure, 2023 Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy have been going head‐to‐head for the past 20 years with similar outcomes and mortality rates, although contemporary myectomy seems to materialize its superiority ...
Alexandru Achim +5 more
doaj +1 more source
Advanced Science, EarlyView.Perivascular matrix densification promotes the emergence of aberrant endothelial tip cells (ATECs) that invade and persist within fibrotic microenvironments. Using in vivo lineage tracing and a human microvessel model, this study shows that fibrous matrix cues destabilize VE‐cadherin–mediated junctions to gate TGF‐β signaling, inducing a pro ...
Jingyi Xia +17 more
wiley +1 more source